Iteos Therapeutics, INC Schedule 13D activist filings

Concentra Biosciences has successfully completed its tender offer and subsequent merger to acquire ITeos Therapeutics, making it a wholly-owned subsidiary.

iTeos Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $10.047 per share in cash plus one contingent value right.

Tang Capital Management and its affiliates have disclosed a 9.99% beneficial ownership stake in ITeos Therapeutics, Inc., transitioning from a passive 13G filing to an active 13D, indicating potential future discussions regarding strategic alternatives.

RA Capital Management, L.P. and its affiliates have significantly reduced their beneficial ownership in ITEOS THERAPEUTICS, INC. through a series of warrant exercises and open market sales, bringing their stake below the 5% threshold.

Investment firm EcoR1 Capital, LLC and its affiliates have disclosed a substantial 27.9% beneficial ownership stake in iTeos Therapeutics, Inc., acquired for investment purposes.

A group of investment entities and individuals, including MPM BioVentures and UBS Oncology Impact Fund, have sold 2,680,732 shares of ITEOS THERAPEUTICS, INC. common stock for over $20 million, resulting in their collective beneficial ownership falling below the 5% threshold.

RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, revealing a reduced beneficial ownership in iTeos Therapeutics, Inc. to 9.9% following recent open market sales.